Black Diamond Financial LLC Acquires 443 Shares of Eli Lilly and Company (NYSE:LLY)

Black Diamond Financial LLC raised its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 41.1% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,522 shares of the company’s stock after purchasing an additional 443 shares during the period. Black Diamond Financial LLC’s holdings in Eli Lilly and Company were worth $1,378,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Angeles Investment Advisors LLC boosted its holdings in Eli Lilly and Company by 61.5% in the second quarter. Angeles Investment Advisors LLC now owns 1,085 shares of the company’s stock valued at $982,000 after acquiring an additional 413 shares in the last quarter. Fairfield Financial Advisors LTD bought a new stake in Eli Lilly and Company during the 2nd quarter valued at approximately $12,866,000. Brown Brothers Harriman & Co. grew its holdings in shares of Eli Lilly and Company by 16.2% during the 2nd quarter. Brown Brothers Harriman & Co. now owns 18,660 shares of the company’s stock worth $16,894,000 after acquiring an additional 2,599 shares during the period. Quilter Plc raised its position in shares of Eli Lilly and Company by 9.9% in the 2nd quarter. Quilter Plc now owns 8,888 shares of the company’s stock worth $8,047,000 after acquiring an additional 800 shares in the last quarter. Finally, Tennessee Valley Asset Management Partners lifted its stake in shares of Eli Lilly and Company by 25.2% in the 2nd quarter. Tennessee Valley Asset Management Partners now owns 373 shares of the company’s stock valued at $338,000 after purchasing an additional 75 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.2 %

Shares of NYSE:LLY opened at $923.71 on Monday. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. Eli Lilly and Company has a 1 year low of $516.57 and a 1 year high of $972.53. The company has a market cap of $877.92 billion, a P/E ratio of 136.04, a PEG ratio of 2.79 and a beta of 0.42. The stock’s fifty day moving average price is $897.12 and its 200-day moving average price is $833.89.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. Sell-side analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 10th. Investors of record on Thursday, August 15th were issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 0.56%. The ex-dividend date was Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is currently 76.58%.

Insiders Place Their Bets

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total transaction of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at approximately $91,109,731,514.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders sold 451,900 shares of company stock valued at $418,732,178. Company insiders own 0.13% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price target (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research report on Monday, September 9th. Morgan Stanley reissued an “overweight” rating and set a $1,106.00 price target on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Friday. Finally, Evercore ISI raised shares of Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.